Repurposing a Potent MDM2 Inhibitor for Leukemia Treatment
Application
VERU-111, also known as sabizabulin, is a potent microtubule inhibitor and, notably, an MDM2 inhibitor. This repurposed compound demonstrates remarkable efficacy in the treatment of Acute Myeloid Leukemia (AML).
Key Benefits
Unique dual-action functionality as a microtubule and MDM2 inhibitor.
Successful inhibition of MDM2, an oncogene...
Published: 4/23/2024
Contributor(s): Deborah DeRyckere, Muxiang Zhou, Lu Bing Gu, Douglas Graham, Tao Liu
|
Drug Platform for L-Asparaginases for the Treatment of Leukemias
Application
A novel humanized therapeutic L-asparaginase compound to treat acute lymphoblastic leukemia (ALL) and other cancers.
Key Benefits
A novel drug discovery platform for developing asparaginase-based compounds to treat leukemias and other cancers.
The derivatives could exhibit less immunogenicity and systemic toxicity than FDA-approved...
Published: 3/1/2024
Contributor(s): Sunil Raikar, Christopher Doering, H. (Harold) Trent Spencer, Kristopher Knight, Harrison Brown
|
ONC201 for the Treatment of Vascular Aneurysms
Application
A repurposed therapeutic for the preventative and treatment of aneurysms.
Key Benefits
A repurposed cancer drug that targets cells known to be damaged during the progression of an aneurysm.
The drug has been tested within an animal model of aortic aneurysms, where it prevented the severe complications of the disease and protected the...
Published: 3/1/2024
Contributor(s): Alejandra Maria San Martin
|
Small Molecules for Treating Cystic Fibrosis
ApplicationSmall molecule compounds to potentiate most common type of CFTR mutation in cystic fibrosis patients.Key BenefitsPotentiates ΔF508-hCFTR mutation, addressing more than 60 percent of CF patients. Market SummaryCystic fibrosis transmembrane conductance regulator (CFTR) is a membrane protein and ion channel that malfunctions in the genetic...
Published: 7/28/2023
Contributor(s): Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
|
Microfluidic and Organotypic Tumor Slice Culture Drug Testing Platform for Individualized Cancer Therapy
Application
A drug combination screening/testing platform for individualized cancer therapy.
Key Benefits
Rapid screening of effective drug combination.
Integrated tumor microenvironment.
Identifying personalized therapy for individual cancer patient.
Market Summary
Traditional two-dimensional (2D) in vitro culture models for drug development...
Published: 4/23/2024
Contributor(s): Tobey John MacDonald, Anna Kenney, Abhinav Dey, YongTae (Tony) Kim
|
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
Application
Therapeutic use of miR-483 mimic for treating aortic valve clarification.
Key Benefits
MiR-483 or mimics of miR-483 could be used as a therapeutic.
Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification.
Market Summary
Aortic stenosis (AS) is the most common type of heart...
Published: 4/8/2024
Contributor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
|
HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform
Application
High Throughput Screening for identifying effective immuno-modulators.
Key Benefits
HT screening platform replicating complex immune medicated response to facilitate discovery of small molecule immunomodulatory agents.
Simplicity and dual readouts of the design enable the screening of large chemical libraries to identify compounds...
Published: 4/23/2024
Contributor(s): Xiulei Mo, Haian Fu
|
Multifunctional Drug and Immune Modulator Delivery Nanoparticles for the Treatment of Cancer Patients with Comorbid Atherosclerosis
Application
A multifunctional immuno-therapy nanoparticle (PD1Y-HANP/Avasimbe) that has ability of targeting and inhibiting immune checkpoint PDL-1 while producing therapeutic effects on tumors and atherosclerosis.
Key Benefits
Multifunctional immunotherapy for cancer patients with atherosclerosis.
Shown to inhibit tumor growth and prevention...
Published: 4/23/2024
Contributor(s): Lily Yang, Lei Zhu
|
Mitigation of Negative Effects of Melphalan on Cardiomyocytes with N-acetyl-L-cysteine (NAC) Treatment
Application
NAC (N-acetyl-L-cystine) as an antioxidant to reduce chemotherapy induced oxidative stress and cardiotoxicity.
Key Benefits
Mitigates cardiotoxic side effects of alkylating agent, melphalan in human cardiomyocytes.
Market Summary
Melphalan is a chemotherapeutic commonly used to treat various cancers including multiple myeloma,...
Published: 11/27/2023
Contributor(s): Chunhui Xu, Anant Mandawat, Rui Liu
|
Small Molecule Compound to Treat Neurological Diseases
Application
NMDAR agents for the treatment of various neurological diseases.
Key Benefits
Exemplary compound EU1180-490 is a potent and selective potentiator of GluN1/GluN3 NMDARs.
The compound has excellent Lipinski drug-like properties including low molecular weight and cLogP, as well as water solubility.
The initial studies have determined...
Published: 4/23/2024
Contributor(s): Dennis Liotta, Stephen Traynelis, Hongjie Yuan, Matthew Epplin, Samantha Summer, David Menaldino, Leon Jacobs, Adam McCallum
|